Compare GSK plc (GSK) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Modine Manufacturing Company — how do they compare? GSK plc trades at $46.83 (market cap $95.18B), while Modine Manufacturing Company trades at $185.47 (market cap $10.06B). The key difference: GSK plc is far larger — about 9.5× Modine Manufacturing Company's market cap, and GSK plc pays a 3.86% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Modine Manufacturing Company for 33 Days on average.
| GSK | MOD | |
|---|---|---|
Market Cap | $95.18B | $10.06B |
Volume | 5,852,596 | 1,340,605 |
Sector | Health | Industrials |
52-Week High | $61.18 | $283.95 |
52-Week Low | $43.24 | $110.73 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $115.25B | $10.49B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 0.13% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 15.1 and EV/EBITDA of 9.0. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for growth beyond upcoming HIV patent expirations.
GSK presents a balanced investment case with solid profitability (29.7% ROE) offset by near-term headwinds. The stock offers value at current levels but faces execution risks from pipeline development and patent cliffs. Analyst sentiment leans cautious with 55% hold ratings, suggesting moderate upside potential with careful risk management required.
Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.
The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
